

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 Date Submitted: July 16, 2002
 (Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 10/014,785
 Filing Date 12/14/2001
 First Named Inventor Chensheng LI
 Group Art Unit 1614
 Examiner Name Unassigned
 Attorney Docket Number 041457-0635

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
JL		4,213,978		Bodor et al.	July 22, 1980	
		6,277,892	B1	Deckner et al.	August 21, 2001	
		5,622,944		Hale et al.	April 22, 1997	
		5,948,434		Labrie	September 7, 1999	
		5,474,783		Miranda et al.	December 12, 1995	
		6,024,976		Miranda et al.	February 15, 2000	
		5,656,285		Sablotsky et al.	August 12, 1997	
		6,303,141	B1	Fischer et al.	October 16, 2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
JL		WO	00/66104	A2	Millennium Pharmaceuticals, Inc.	11-09-2000		
		WO	93/23019	A1	SRI International	11-25-1993		
		EP	0 439 430	A2	CIBA-GEIGY AG	07-31-1991		
		EP	0 468 875	B1	ADIR ET COMPAGNIE	01-29-1992		X
		WO	02/03970	A2	Anmelder	01-17-2002		X

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
JL		Nicholas Bodor, Jack Zupan and Sally Selk; Improved Delivery Through Biological Membranes VII. Dermal Delivery of Cromoglycic Acid (Cromolyn) Via Its Prodrugs ; International Journal of Pharmaceutics, (November 1980); Vol. 7, no. 1; pp. 63-75; Elsevier/North-Holland Biomedical Press; The Netherlands	
JL		C. Desbonnet, A.H. Kennedy, S.C. McNeill, E. Wakshull, R.O. Potts; "Abstract for" Transdermal Drug Transport and Metabolism Are Correlated ; Clinical Research; (April 1988); pp. 640A; Vol. 36, No. 3; The American Federation for Clinical Research; Washington, D.C.	

Examiner Signature

Lris Stal

Date Considered

7/30/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: July 16, 2002

Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/014,785
Filing Date	12/14/2001
First Named Inventor	Chensheng LI
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	041457-0635

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
JS	3	Milind M. Narurkar and Ashim K. Mitra; "Abstract for" Improved Ocular Delivery of Idoxuridine Using The Prodrug Approach ; Pharmaceutical Research-Official Journal of the American Association of Pharmaceutical Scientists; (October 1988); Vol. 5, No. 10; pp. S-98/PD 904; Plenum Press, New York and London	
	(1)	Fort, James Joseph, Ph.D. and Ashim K. Mitra; Investigation Of A Series Of Methotrexate Dialkyl Esters As Potential Prodrugs For Topical Delivery ; Dissertation Abstracts International-B The Sciences and Engineering; Health Sciences, Pharmacy; (May 1990); pp. 5005-B; Vol. 50, No. II; U-M-I	
	5	Beall, Howard D., Ph.D. and K.B. Sloan; Bioreversible Derivatives Of 5-Fluorouracil (5FU): Improving Dermal And Transdermal Delivery With Prodrugs ; Dissertation Abstracts International-B The Sciences and Engineering; Chemistry, Pharmaceutical; (August 1992); pp. 859-B; Vol. 53, No. 2; U-M-I	
	(6)	Hiroto Bando, Mikiko Sahashi, Toshihide Takagi, Fumiyoshi Yamashita, Yoshinobu Takakura, Mitsuru Hashida; Analysis Of In Vitro Skin Penetration Of Acyclovir Prodrugs Based On A Diffusion Model With A Metabolic Process ; International Journal of Pharmaceutics; (June 17, 1996); pp. 91-102; Vol. 135, Nos. 1 and 2; Elsevier Science B.V.	
	(7)	Hiroto Bando, Mikiko Sahashi, Saya Mohri, Fumiyoshi Yamashita, Yoshinobu Takakura, Mitsuru Hashida; In Vivo Skin Penetration Enhancement Of Acyclovir By Theoretical Design Of Prodrug-Enhancer Combination ; International Journal of Pharmaceutics; (December 6, 1996); pp. 103-113; Vol. 145, Nos. 1 and 2; Elsevier Science B.V.	
	8	Hiroto Bando, Mikiko Sahashi, Fumiyoshi Yamashita, Yoshinobu Takakura, Mitsuru Hashida; In Vivo Evaluation of Acyclovir Prodrug Penetration and Metabolism Through Rat Skin Using a Diffusion/Bioconversion Model ; Pharmaceutical Research; Journal of Pharmaceutical Sciences; (June 1997); pp. 56-62; Vol. 86, No. 6; American Pharmaceutical Association and the American Chemical Society, United States of America	
	9	G.C. Santus and R.W. Baker; Transdermal Enhancer Patient Literature ; Journal of Controlled Release; (1993); pp. 1-20; Vol. 25; Elsevier Science Publishers B.V.	
	10	Hiroto Bando, Saya Mohri, Fumiyoshi Yamashita, Yoshinobu Takakura, and Mitsuru Hashida; Effects of Skin Metabolism on Percutaneous Penetration of Lipophilic Drugs ; Journal of Pharmaceutical Sciences; (June 1997); pp. 759-761; Vol. 86, No. 6; The American Chemical Society and American Pharmaceutical Association	
	(11)	Gillian P. McMahon, Shane J. O'Connor, Desmond J. Fitzgerald, Sylvie le Roy, Mary T. Kelly; Determination of Aspirin and Salicylic Acid in Transdermal Perfusates ; Journal of Chromatography B; (April 10, 1998); pp. 322-327; Vol. 707, Nos. 1 and 2; Elsevier Science B.V.	
	12	H. Bundgaard; Design and Application of Prodrugs ; A Textbook of Drug Design and Development; (1991); pp. 113-191; Chapter 5; Harwood Academic Publishers, Switzerland	
2y	13	Eugene R. Cooper; Increased Skin Permeability for Lipophilic Molecules ; Journal of Pharmaceutical Sciences; (August 1984); pp. 1153-1156; Vol. 73, No. 8; American Pharmaceutical Association, United States of America	

Examiner
Signature

Jas Ghalib

Date
Considered

9/30/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 17, 2003

(use as many sheets as necessary)

Complete if Known

Application Number	10/014,785
Filing Date	12/14/2001
First Named Inventor	Chensheng LI
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	041457-0635




Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
J		5,656,286		Miranda et al.	08/12/1997	
		5,925,372		Berner et al.	07/20/1999	
		4,847,250		Alexander et al.	07/11/1989	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
J		EP	0 458 641	A2	THE WELLCOME FOUNDATION LIMITED	05/23/1991		
		WO	99/42111	A1	CYCLOPS, EHF. [IS/IS]	08/26/1999		
		EP	0 581 587	A2	TANABE SEIYAKU CO., LTD	07/28/1993		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
J		T. LOFTSSON, <i>Effects of Cyclodextrins and Polymers on Transdermal Drug Delivery</i> , <u>Proceed. Intern. Symp. Control. Ref., Bioact. Mater.</u> , (1996), pp. 194-195., 23, Control Release Society, Inc	

Examiner Signature

Jis Ghal

Date Considered

9/30/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.